Navigating the procurement of high-purity research compounds requires strict adherence to analytical verification and supply chain integrity. Principal investigators and laboratory researchers seeking to buy Dihexa peptide for in vitro and preclinical models require fully characterized reagents backed by rigorous third-party analytical testing.
Navigating the procurement of high-purity research compounds requires strict adherence to analytical verification and supply chain integrity. Principal investigators and laboratory researchers seeking to buy Dihexa peptide for in vitro and preclinical models require fully characterized reagents backed by rigorous third-party analytical testing.
Verified research-grade Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) can be purchased through specialized scientific suppliers like PX1 Research. Intended strictly for laboratory, in vitro, and preclinical investigation, research-grade Dihexa requires independent HPLC purity verification above 98%, mass spectrometry mass-validation, and lot-specific Certificates of Analysis (COAs) to guarantee analytical reproducibility across experimental protocols.
When purchasing reagents for advanced cellular or molecular assays, procurement specialists must ensure that compounds are free from counter-ion contamination, residual synthesis solvents, and heavy metals. Obtaining authentic Dihexa from established American suppliers ensures full traceability from synthesis to shipment, eliminating batch-to-batch variability that can compromise quantitative assay data.
PX1 Research provides qualified institutions with research-grade peptides produced under stringent quality control standards. Laboratories looking to equip their workflows with validated compounds can review our complete catalog of all peptides or establish specialized institutional accounts through our wholesale program.
Dihexa, also identified in biochemical literature as PNB-0408, is an oligopeptide derivative designed to possess enhanced metabolic stability compared to native peptide sequences. Derived structurally from angiotensin IV, Dihexa exhibits a hexanoic acid modification at the N-terminus paired with a modified aminohexanoic amide structure. Its systematic chemical designation is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, with an approximate molecular weight of 501.7 g/mol.
Unlike short-chain native linear peptides that rapidly succumb to proteolytic degradation by endogenous peptidases in cell culture media, Dihexa’s hydrophobic N-terminal hexanoyl group and modified backbone impart significant stability. In solid state, the compound presents as a white to off-white lyophilized powder. It demonstrates selective solubility parameters, dissolving readily in organic co-solvents such as dimethyl sulfoxide (DMSO) and ethanol, while requiring specific buffer formulations for stable aqueous dissolution.
Understanding these physical properties is critical when designing in vitro incubations or biochemical binding assays. Researchers evaluating the structural dynamics of small molecule peptidomimetics frequently reference the comprehensive research library for data on molecular stability, solubility limits, and structural characterization.
The primary biochemical target of Dihexa in experimental models is the Hepatocyte Growth Factor (HGF) and its receptor tyrosine kinase, c-Met. Preclinical studies suggest that Dihexa binds with high affinity to HGF (dissociation constant in the picomolar range), effectively facilitating the dimerization of HGF. This conformational stabilization enhances HGF's capacity to bind and activate the cell-surface c-Met receptor.
Upon ligand binding, the c-Met intracellular tyrosine kinase domain undergoes autophosphorylation, initiating downstream signaling cascades including the Ras/MAPK, PI3K/Akt, and STAT3 pathways. In neuronal and non-neuronal cellular assays, activation of these pathways regulates key physiological responses, including cell survival, cytoskeletal remodeling, and target gene expression.
In vitro data indicate that Dihexa-mediated c-Met activation promotes robust spinogenesis and synaptogenesis in primary hippocampal culture models. Experimental observations demonstrate increased dendritic spine density and the formation of functional synaptic connections at concentrations significantly lower than baseline trophic factors like brain-derived neurotrophic factor (BDNF).
Scientific literature regarding Dihexa focuses heavily on its neurogenic potential in cell cultures and animal models of cognitive decline and neurodegeneration. In rodent models featuring age-related cognitive deficits or chemically induced neurotoxicity (such as scopolamine-induced amnesia models), administration of Dihexa in controlled experimental paradigms resulted in measurable improvements in spatial learning and memory retrieval tasks.
Histological analyses of brain tissue harvested from treated animal models revealed increased postsynaptic density-95 (PSD-95) expression and enhanced synaptophysin labeling. These biochemical markers correlate directly with structural synaptic plasticity in the CA1 and dentate gyrus regions of the hippocampus.
Furthermore, preclinical investigations have explored Dihexa in models of traumatic brain injury (TBI) and neurodegenerative disease phenotypes. The compound's capacity to cross the blood-brain barrier in rodent assays—owing to its lipophilic structural modifications—makes it a prominent tool for investigating non-invasive neurotrophic enhancement strategies in laboratory settings.
When designing protocols to investigate synaptogenesis or neuroprotection, researchers frequently compare Dihexa to other established neurogenic research peptides. While Dihexa acts primarily as an HGF/c-Met agonist, compounds such as Semax operate predominantly by modulating central BDNF and nerve growth factor (NGF) expression, alongside melanocortin receptor interaction. In contrast, Selank exerts its effects via modulation of the GABAergic system and enkephalin stability, offering a distinct mechanism aimed at neurochemical balancing rather than direct receptor tyrosine kinase activation.
Another relevant benchmark in neurodegenerative preclinical literature is Cerebrolysin, a complex mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue. While Cerebrolysin provides a broad spectrum of neurotrophic factors targeting multiple pathways simultaneously, Dihexa represents a targeted, single-entity small molecule peptidomimetic with precise molecular targets.
The following table summarizes the primary mechanisms and experimental targets of these compounds in preclinical research:
To maintain scientific rigor and ensure reproducibility, researchers looking to buy Dihexa peptide must rigorously evaluate analytical documentation. Every batch of research peptides supplied by PX1 Research undergoes thorough quality testing at ISO 17025 accredited, independent laboratories.
A comprehensive Certificate of Analysis (COA) for Dihexa must detail three critical analytical metrics: purity verification via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), molecular weight identity via Electrospray Ionization Mass Spectrometry (ESI-MS), and biological contaminant screening.
RP-HPLC analysis confirms peptide purity by separating target molecules from synthesis byproducts, requiring a single sharp peak demonstrating >98% purity. ESI-MS verifies that the observed mass-to-charge ratio matches the theoretical molecular weight of Dihexa (501.7 Da). Additionally, bacterial endotoxin testing via the Limulus Amebocyte Lysate (LAL) assay ensures that endotoxin levels remain strictly under <0.01 EU/mg, preventing baseline cellular toxicity in sensitive in vitro primary cell cultures.
Proper reconstitution and storage procedures are essential to maintain the structural stability of Dihexa in laboratory environments. Dihexa is supplied as a lyophilized (freeze-dried) powder sealed under inert gas. Upon receipt, unopened vials should be stored at -20°C or -80°C for long-term stability, protected from light and moisture.
Because Dihexa exhibits hydrophobic character due to its N-terminal hexanoyl group, direct reconstitution in pure water or standard phosphate-buffered saline (PBS) may result in incomplete dissolution or precipitation. The recommended protocol involves initial solubilization in anhydrous DMSO or sterile ethanol to create a concentrated stock solution.
Once fully dissolved in solvent, the stock can be diluted into working buffer or cell culture media to achieve desired experimental concentrations, ensuring final solvent concentrations remain below cytotoxic thresholds (typically <0.1% v/v DMSO in cell cultures). Reconstituted liquid aliquots should be stored at -80°C to prevent freeze-thaw degradation cycles.
Evaluating chemical suppliers requires analyzing transparency, manufacturing standards, and quality control systems. Substandard suppliers frequently offer peptides without batch-specific documentation or rely on generic, unverified lab reports that lack raw chromatographic data.
PX1 Research maintains complete operational transparency by manufacturing research compounds in USA-based, GMP-compliant facilities. Every lot is subjected to dual-stage analytical verification, guaranteeing that the material received by your research institution matches theoretical standards exactly.
When purchasing reagents for high-throughput screening or publication-grade studies, verify that the supplier offers full lot traceability, publicly accessible third-party COAs, secure cold-chain handling, and dedicated institutional support. PX1 Research ships directly from facilities in California and Arizona, providing fast, reliable same-day dispatch for orders placed Monday through Friday.
Dihexa is a potent biochemical tool intended exclusively for in vitro, biochemical, and preclinical laboratory research. It is strictly not for human consumption, clinical use, or diagnostic procedures. Laboratory personnel handling Dihexa must adhere to standard Biosafety Level 1 (BSL-1) or Level 2 (BSL-2) practices depending on the cellular or animal models employed.
Appropriate Personal Protective Equipment (PPE)—including nitrile gloves, lab coats, and safety eyewear—must be worn at all times when handling lyophilized powders or stock solutions. Powder manipulation should ideally occur inside a certified chemical fume hood or laminar flow cabinet to avoid aerosolization or accidental inhalation.
Unused solutions or contaminated labware must be disposed of according to institutional hazardous chemical waste guidelines. Detailed Safety Data Sheets (SDS) outlining chemical hazard identification, first-aid measures, and spill containment procedures are available upon request from PX1 Research.
What is Dihexa and what is its chemical structure?
Dihexa (PNB-0408) is an oligopeptide derivative derived from angiotensin IV, chemically designated as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide. It is studied in preclinical research for its high-affinity binding to Hepatocyte Growth Factor (HGF) and subsequent activation of the c-Met receptor pathway.
Where can verified research-grade Dihexa be purchased with a COA?
Research-grade Dihexa can be purchased directly from PX1 Research. PX1 provides fully verified compounds manufactured in US-based GMP-compliant facilities, complete with batch-specific third-party COAs detailing HPLC purity, mass spectrometry mass confirmation, and endotoxin levels.
How does Dihexa interact with the c-Met/HGF receptor signaling axis in vitro?
In vitro studies demonstrate that Dihexa binds to HGF with picomolar affinity, stabilizing HGF dimerization. This facilitates the autophosphorylation and activation of the c-Met tyrosine kinase receptor, driving downstream intracellular cascades such as PI3K/Akt and Ras/MAPK involved in synaptogenesis and cellular survival.
What solvents are recommended for reconstituting Dihexa in laboratory settings?
Due to its hydrophobic N-terminal hexanoyl modification, lyophilized Dihexa should first be dissolved in anhydrous DMSO or sterile ethanol to form a concentrated stock solution. This stock can subsequently be diluted into aqueous buffers or culture media for experimental use.
What purity level should be verified on a Dihexa Certificate of Analysis?
A high-quality Dihexa reagent should display a purity of ≥98% as measured by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). Additionally, mass spectrometry should confirm the expected molecular weight (501.7 Da), and endotoxin assays should show levels under 0.01 EU/mg.
How does Dihexa differ from Semax or Selank in preclinical models?
While Dihexa acts directly on the HGF/c-Met receptor axis to promote synaptogenesis, Semax works primarily by upregulating BDNF/NGF expression and modulating melanocortin receptors, and Selank acts mainly on GABAergic neurotransmission and enkephalin enzymatic stability.
What are the recommended storage conditions for lyophilized Dihexa?
Lyophilized Dihexa should be stored desiccated at -20°C or -80°C for long-term stability. Once reconstituted in organic stock solvents like DMSO, aliquots should be kept frozen at -80°C to prevent degradation from repeated freeze-thaw cycles.
Is Dihexa approved for human consumption or clinical administration?
No. Dihexa is supplied strictly as a research compound for in vitro laboratory assays, biochemical binding studies, and animal models. It is not approved by the FDA for human use, therapeutic application, or clinical diagnosis.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.